Pacific Edge (PEB)

Business description

Pacific Edge develops and sells a portfolio of molecular diagnostic tests based on biomarkers for the early detection and management of cancer. Tests utilising its Cxbladder technology for detecting and monitoring bladder cancer are sold in the US, New Zealand and Australia.

Early signs of revenue traction

Update | Pharmaceutical & healthcare | 16/12/2014

Pacific Edge has reported encouraging headline results for its fiscal H115 ending in September. Sales reached NZ$1.59m, of which NZ$714k was attributed to trading revenue, a 774% increase from the previous year. The net loss of NZ$4.9m in the six months to September was roughly in line with the previous six-month period, indicating continued lean management and cost control. Additionally, the company has announced the launch of complementary bladder test Cxbladder Triage in New Zealand. We value Pacific Edge at NZ$369m (previously NZ$338m).

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.NZ$167.9m
Last closeNZ$0.360
High / Low (52 weeks)NZ$0.6 / NZ$0.3
Stock market listingNZ
Forecast net cash (NZ$m)22.8
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual1.49.6(36.6)
Relative *2.27.6(43.8)

* % Relative to local index

Company news